Maia Biotech completes enrollment for THIO-101 Phase 2 NSCLC trial of ateganosine plus cemiplimab
Bitget2026/10/07 12:15Maia Biotechnology hit an enrollment milestone across ongoing Phase 2 THIO-101 and pivotal Phase 3 THIO-104 trials in non-small cell lung cancer. Interim Phase 2 results have already been presented, indicating the combination regimen kept more patients’ disease from worsening than chemotherapy. Phase 2 enrollment is complete for the cohort pairing ateganosine with cemiplimab, supporting the program’s path toward a readout. Phase 3 enrollment reached 65% of a 100-patient year-end goal, positioning the study for an interim analysis planned for 2027. FDA Fast Track status for ateganosine in NSCLC remains a key regulatory advantage as the company advances toward potential registration. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610070815PRIMZONEFULLFEED9840606) on October 07, 2026, and is solely responsible for the information contained therein.
- Maia Biotechnology hit an enrollment milestone across ongoing Phase 2 THIO-101 and pivotal Phase 3 THIO-104 trials in non-small cell lung cancer.
- Interim Phase 2 results have already been presented, indicating the combination regimen kept more patients’ disease from worsening than chemotherapy.
- Phase 2 enrollment is complete for the cohort pairing ateganosine with cemiplimab, supporting the program’s path toward a readout.
- Phase 3 enrollment reached 65% of a 100-patient year-end goal, positioning the study for an interim analysis planned for 2027.
- FDA Fast Track status for ateganosine in NSCLC remains a key regulatory advantage as the company advances toward potential registration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Crypto prices
More
